Focus: Paradromics is a pre-revenue biotechnology company focused on developing brain-computer interface (BCI) technology for neurological disorders. The company is in early-stage development with minimal public financial disclosure and operates from Austin, Texas.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Growing — net +6 jobs in 30d
9 jobs added vs 3 removed. Steady team buildout.
Paradromics is a high-risk, high-reward early-stage BCI play suitable for engineers seeking equity upside and technical innovation, but inappropriate for those prioritizing compensation certainty or near-term career stability.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Paradromics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Paradromics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles